UTHR Q4 2020 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$385M+23.7% YoY

Gross Profit

$350M91.0% margin

Operating Income

$65M17.0% margin

Net Income

$99M25.7% margin

EPS (Diluted)

$2.19

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

$126M

Free Cash Flow

$114M

Stock-Based Comp.

$94M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.2B

Stockholders' Equity

$3.4B

Cash & Equivalents

$739M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$385M	$311M	+23.7%
Gross Profit	$350M	$282M	+24.0%
Operating Income	$65M	$64M	+2.8%
Net Income	$99M	$53M	+87.8%

Revenue Segments

Remodulin

$128M51%

Orenitram

$74M29%

Unituxin

$30M12%

Adcirca

$22M9%